A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies Journal Article
| Authors: | Tse, A. N.; Wu, N.; Patel, D.; Haviland, D.; Kemeny, N. |
| Article Title: | A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies |
| Abstract: | Purpose: To determine the maximum tolerated dose and duration of hepatic arterial infusion (HAI) gemcitabine in patients with unresectable hepatic metastases from colorectal cancer or primary hepatic malignancies. Methods: Patients received weekly gemcitabine via the side-port of an implantable HAI pump for 3 weeks in a 28-day cycle. During the dose escalation phase, increasing doses of HAI gemcitabine (800, 1,000, 1,200, and 1,500 mg/m<sup>2</sup>) were given at a fixed dose-rate of 10 mg/(m<sup>2</sup> min). This was followed by the infusion duration escalation (IDE) phase, in which HAI gemcitabine at 1,000 mg/m<sup>2</sup> was given over increasing lengths of time (200, 300, and 400 min). To estimate hepatic drug extraction, the pharmacokinetics of HAI gemcitabine was compared with those of intravenous gemcitabine given at the same dose-rate to the same patient in the IDE phase. Results: Twenty-eight of 30 patients were evaluable. HAI gemcitabine was well tolerated up to 1,500 mg/m<sup>2</sup> given at 10 mg/(m<sup>2</sup> min) and up to 1,000 mg/m <sup>2</sup> infused over 400 min. There were no protocol-defined dose-limiting toxicities. One patient with cholangiocarcinoma had a partial response. Hepatic extraction of gemcitabine seems highly variable among patients and does not correlate with the length of HAI infusion. Conclusions: Hepatic arterial infusion of gemcitabine given at doses higher or longer than the recommended systemic dose of 1,000 mg/m<sup>2</sup> over 30 min is well tolerated. For future studies, we recommend an infusion of 1,500 mg/m<sup>2</sup> at a fixed dose-rate of 10 mg/(m<sup>2</sup> min). © 2009 Springer-Verlag. |
| Keywords: | adult; clinical article; treatment outcome; treatment response; aged; middle aged; clinical trial; drug tolerability; fatigue; neutropenia; diarrhea; drug dose reduction; side effect; skin toxicity; treatment duration; carcinoma, hepatocellular; liver neoplasms; gemcitabine; cancer patient; colorectal cancer; adenocarcinoma; edema; liver toxicity; multiple cycle treatment; bone marrow suppression; antimetabolites, antineoplastic; leukopenia; thrombocytopenia; creatinine; creatinine blood level; antineoplastic activity; dose-response relationship, drug; aspartate aminotransferase blood level; drug dose escalation; rash; liver metastasis; liver; disease progression; drug infusion; bile duct carcinoma; cholangiocarcinoma; alkaline phosphatase blood level; bile duct obstruction; maximum tolerated dose; phase 1 clinical trial; drug dose increase; deoxycytidine; bilirubin blood level; hepatic arterial infusion; infusion pumps, implantable |
| Journal Title: | Cancer Chemotherapy and Pharmacology |
| Volume: | 64 |
| Issue: | 5 |
| ISSN: | 0344-5704 |
| Publisher: | Springer |
| Date Published: | 2009-10-01 |
| Start Page: | 935 |
| End Page: | 944 |
| Language: | English |
| DOI: | 10.1007/s00280-009-0945-5 |
| PUBMED: | 19221752 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 3" - "Export Date: 30 November 2010" - "CODEN: CCPHD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work